Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Algeta
Algeta
Activities:
Manufacturing
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Pharmaceutical
Thomas Ramdahl appointed as Managing Director of Algeta
Bayer has completed the acquisition of the Norwegian developer of cancer drugs
Research & Development
Algeta appoints Chief Scientific Officer
Dr Andreas Menrad takes responsibility for the Norwegian company\'s research strategy
Manufacturing
Algeta opens commercial production facility for Xofigo in Norway
The plant for the manufacture of the cancer treatment is based at the Institute for Energy Technology (IFE) in Norway
Manufacturing
Cobra Biologics and Algeta sign monoclonal antibody manufacturing agreement
Cobra to provide cell line development, cell banking, process development, scale-up, GMP production and stability studies
Norwegian cancer therapeutics developer appoints president
Jeffrey Albers takes up the role at Algeta US
Regulatory
Anticancer agent – radium-223 chloride
Radiotherapy commonly involves directing beams of radioactive particles at the tumour, or a radioactive source being placed within the body
Research & Development
Algeta wins grant to develop alpha-pharmaceuticals based on Thorium-227
Norwegian firm to create pipeline of cancer-destroying drugs
Subscribe now